Xilio Therapeutics, Inc. - XLO STOCK NEWS

Xilio Therapeutics, Inc. (Nasdaq: XLO) will host a live virtual program on December 1, 2022, at 12:30 p.m. ET to discuss its clinical-stage molecule, XTX301, an engineered IL-12 aimed at treating immunologically 'cold' tumors. Dr. Diwakar Davar from UPMC Hillman Cancer Center will explain the significance of IL-12 in stimulating anti-tumor immunity and the differences between cold and hot tumors. Xilio executives will also outline the Phase 1 trial for XTX301 and its anticipated timeline. The event will include a Q&A session.

Xilio Therapeutics (Nasdaq: XLO) reported significant progress in its clinical-stage pipeline, showcasing tumor-activated therapies, XTX202 and XTX301. The ongoing Phase 1 trial for XTX202 has successfully reached a target dose of 1 mg/kg, showing increased CD8+ effector and NK cells without vascular leak syndrome. XTX301 received FDA IND clearance, with patient enrollment expected in early 2023. The company reported $139.1 million in cash as of September 30, 2022, which is projected to last until Q2 2024, despite a net loss of $19.8 million for Q3 2022.

Xilio Therapeutics, Inc. (Nasdaq: XLO) announced its participation in a virtual fireside chat at the Cowen 6th Annual IO Next Summit on November 11, 2022, at 1:40 p.m. ET. The event can be accessed via live webcast in the Investors & Media section of its website, with a replay available for 30 days post-presentation. Xilio focuses on developing tumor-activated immuno-oncology therapies, using its GPS platform to create biologics targeting the tumor microenvironment, aiming for enhanced anti-tumor activity. Key product candidates include XTX101 and XTX202.

On September 22, 2022, Xilio Therapeutics (Nasdaq: XLO) announced its participation in a fireside chat at the Guggenheim Nantucket Therapeutics Conference, scheduled for September 29, 2022, at 10:15 a.m. ET. A live webcast will be available on the company’s website, with access under the “Events & Presentations” section. This presentation will be archived for 30 days. Xilio is focused on developing tumor-selective immuno-oncology therapies aimed at improving cancer patient outcomes through its proprietary GPS platform.

Xilio Therapeutics has appointed Tomas J. Heyman to its board of directors, enhancing the team with nearly 40 years of biopharmaceutical leadership experience. Heyman previously worked at Johnson & Johnson, overseeing substantial investments in over 120 companies. Additionally, John Maraganore, former CEO of Alnylam Pharmaceuticals, joins as a strategic advisor. These appointments aim to advance Xilio's tumor-selective immunotherapy programs, leveraging their expertise to drive value creation and innovation in cancer treatment.

Xilio Therapeutics, a biotechnology company focused on immuno-oncology therapies, will participate in a virtual fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, at 2:55 p.m. ET. The event will be accessible via a live webcast on the company’s website, with a replay available for 30 days post-event. Xilio is advancing its proprietary GPS platform to engineer tumor-selective cytokines and checkpoint inhibitors, including clinical-stage programs XTX101 and XTX202.

Xilio Therapeutics (Nasdaq: XLO) provided an update on its clinical trials and financials on August 9, 2022. XTX101, a tumor-selective anti-CTLA-4, has exceeded its target dose in a Phase 1 trial, with plans for a Phase 2 trial in MSS colorectal cancer. The company reported a cash position of $159.4 million as of June 30, 2022, expected to sustain operations into the first half of 2024. The second quarter net loss increased to $24.6 million, reflecting a rise in general and administrative expenses. Upcoming milestones include critical data releases for XTX101 and XTX202 in 2023.

Xilio Therapeutics, Inc. (Nasdaq: XLO) announced key leadership changes on June 16, 2022. Martin Huber, M.D., is promoted to president while continuing as head of R&D. Paul Clancy is elected chair of the board, succeeding Dan Lynch, who will serve as a strategic advisor. Clancy has been part of the board since July 2020 and brings extensive financial management experience. Additionally, Robert Ross, M.D., joins the board, enhancing Xilio’s oncology expertise. These leadership changes aim to improve Xilio’s strategic direction and advance its tumor-selective immuno-oncology programs.

Xilio Therapeutics, a biotechnology company focused on tumor-selective immuno-oncology therapies, announced that Dr. Marty Huber will present at the H.C. Wainwright Global Investment Conference on May 25, 2022, at 2:30 p.m. ET. A live webcast will be available on the company’s website, with a replay accessible for 30 days. Xilio is advancing its proprietary GPS platform to create targeted therapies like XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody, and XTX202, a tumor-selective IL-2, aiming to enhance anti-tumor activity while minimizing systemic effects.